CYP19A1 and breast carcinoma: In ERα-positive or HER2-positive breast cancer, there have been a multitude of clinical trials that have combined an antiandrogen or an inhibitor of androgen synthesis with an ERα-degrader, aromatase inhibitor, or an anti-HER2-antibody.